No Data
Novo-Nordisk A/S recorded its largest monthly decline in over 20 years. The long-term outlook remains Bullish, but the short-term rebound is lackluster.
①The Danish weight-loss drug giant Novo-Nordisk A/S has recorded its worst monthly performance in over twenty years; although Analysts remain Bullish on the stock's long-term prospects, there is a lack of catalysts expected to stimulate a rebound in the stock price in the short term. ② Since hitting an all-time high last June, the share price of Novo-Nordisk A/S has faced multiple setbacks.
Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk
Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk Gains Exclusive Rights to Lexicon's Non-incretin Obesity Drug Candidate
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
Novo Nordisk Reports Positive Results From Phase 3B Stride Trial of Ozempic
